Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
25 10 2022
Historique:
received: 28 09 2022
revised: 19 10 2022
accepted: 20 10 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest in developing these vectors as vaccines and therapies against other viruses of health importance such as hepatitis B virus (HBV). Current hepatitis B therapies are not curative; hence, chronic hepatitis B remains the major risk factor for development of liver disease and death in HBV-infected individuals. The ability to induce a robust immune response and high liver transduction efficiency makes adenoviral vectors attractive tools for anti-HBV vaccine and therapy development, respectively. This review describes recent developments in designing adenoviral-vector-based therapeutics and vaccines against HBV infection.

Identifiants

pubmed: 36360178
pii: genes13111941
doi: 10.3390/genes13111941
pmc: PMC9689594
pii:
doi:

Substances chimiques

Viral Vaccines 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Ther. 2011 Jan;19(1):83-92
pubmed: 20959811
Hepatol Commun. 2018 Nov 15;3(1):8-19
pubmed: 30619990
Hum Gene Ther. 1995 Oct;6(10):1343-53
pubmed: 8590739
J Clin Invest. 2021 Mar 1;131(5):
pubmed: 33529172
Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005-9
pubmed: 3029758
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Hum Mol Genet. 2011 Apr 15;20(R1):R7-13
pubmed: 21470977
Mol Ther. 2008 Jul;16(7):1276-82
pubmed: 18461056
Nat Microbiol. 2022 Jul;7(7):974-985
pubmed: 35681012
Nat Commun. 2020 Aug 21;11(1):4207
pubmed: 32826924
Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):907-17
pubmed: 26651252
Mol Ther. 2022 May 4;30(5):1822-1849
pubmed: 35092844
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
J Virol. 2011 May;85(9):4222-33
pubmed: 21325402
Hum Gene Ther. 2008 Dec;19(12):1369-82
pubmed: 18778197
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):724-735
pubmed: 35576953
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Int Immunopharmacol. 2021 Nov;100:108086
pubmed: 34454291
J Virol. 2004 Jun;78(11):5966-72
pubmed: 15140994
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
Mol Ther. 2005 Jul;12(1):107-17
pubmed: 15963926
Mol Ther Nucleic Acids. 2018 Sep 7;12:242-253
pubmed: 30195763
Hum Gene Ther. 2009 Sep;20(9):975-88
pubmed: 19469693
NPJ Vaccines. 2021 Aug 5;6(1):97
pubmed: 34354082
Gene Ther. 2005 Apr;12(7):579-87
pubmed: 15647765
Viruses. 2017 May 22;9(5):
pubmed: 28531167
J Med Virol. 2013 Jun;85(6):1077-84
pubmed: 23588735
Genes (Basel). 2018 Sep 27;9(10):
pubmed: 30262738
Mol Ther. 2020 Nov 4;28(11):2303-2304
pubmed: 33065038
Signal Transduct Target Ther. 2021 Feb 8;6(1):53
pubmed: 33558455
Int J Mol Sci. 2021 Sep 29;22(19):
pubmed: 34638909
Nat Commun. 2021 Nov 25;12(1):6910
pubmed: 34824211
Viruses. 2021 Dec 14;13(12):
pubmed: 34960772
J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
Vaccines (Basel). 2020 Apr 14;8(2):
pubmed: 32295168
Lancet. 2018 Nov 24;392(10161):2313-2324
pubmed: 30496122
Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58
pubmed: 14567964
Gastroenterology. 2019 Jan;156(2):384-399
pubmed: 30268787
Postgrad Med J. 2022 May 1;98(1159):389-394
pubmed: 37066438
Mol Ther. 2013 Oct;21(10):1889-97
pubmed: 23883864
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
J Control Release. 2016 Sep 10;237:78-88
pubmed: 27388756
Antiviral Res. 2015 Jun;118:110-7
pubmed: 25843425
Curr Top Microbiol Immunol. 2004;273:335-57
pubmed: 14674606
J Virol. 2003 Dec;77(24):12931-40
pubmed: 14645549
Front Immunol. 2021 Dec 22;12:745541
pubmed: 35003061
J Virol. 2018 May 14;92(11):
pubmed: 29437961
Biomed Res Int. 2014;2014:718743
pubmed: 25003129
J Virol. 2004 Dec;78(23):13207-15
pubmed: 15542673
Gut. 2022 Mar;71(3):616-626
pubmed: 33563643
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Hum Gene Ther. 2004 Nov;15(11):1022-33
pubmed: 15610603
Sci Transl Med. 2020 Nov 25;12(571):
pubmed: 33239388
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
Nature. 2006 May 11;441(7090):239-43
pubmed: 16625206
J Virol. 2006 Feb;80(4):1959-64
pubmed: 16439551
mBio. 2022 Apr 26;13(2):e0288821
pubmed: 35389262
Mol Ther. 2010 Apr;18(4):754-65
pubmed: 20087317
J Genet Genomics. 2016 May 20;43(5):239-50
pubmed: 27210042
NPJ Vaccines. 2022 Mar 2;7(1):29
pubmed: 35236838
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196-200
pubmed: 8016137
Genes (Basel). 2018 Apr 12;9(4):
pubmed: 29649127
Annu Rev Med. 2022 Jan 27;73:41-54
pubmed: 34609905
Nat Rev Immunol. 2022 Jan;22(1):19-32
pubmed: 34002067
Biol Pharm Bull. 2010;33(9):1540-4
pubmed: 20823571
Viruses. 2021 Jul 02;13(7):
pubmed: 34372506
Mol Ther. 2005 Jan;11(1):66-79
pubmed: 15585407
Mol Ther. 2020 Mar 4;28(3):709-722
pubmed: 31968213
Mol Ther. 2008 Jan;16(1):154-62
pubmed: 17848961
Hum Gene Ther. 2008 Nov;19(11):1325-31
pubmed: 19848584
World J Gastroenterol. 2021 Sep 28;27(36):6025-6038
pubmed: 34629817
Antivir Ther. 2014;19(4):363-73
pubmed: 24296696
NPJ Vaccines. 2021 Dec 20;6(1):157
pubmed: 34930928
Mol Ther. 2006 Feb;13(2):411-21
pubmed: 16337206
J Virol. 2008 Dec;82(23):11705-13
pubmed: 18815305
Drug Metab Pharmacokinet. 2022 Feb;42:100432
pubmed: 34974335
Expert Rev Vaccines. 2017 Aug;16(8):811-832
pubmed: 28573913
ESC Heart Fail. 2022 Apr;9(2):1483-1486
pubmed: 35106967
Front Oncol. 2019 Nov 08;9:1182
pubmed: 31781493
Mol Ther. 2004 Oct;10(4):616-29
pubmed: 15451446
Neuroscience. 2000;95(1):217-26
pubmed: 10619478
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Pharmaceuticals (Basel). 2021 Apr 25;14(5):
pubmed: 33923054
J Virol. 2013 May;87(10):6047-50
pubmed: 23487468
Mol Ther Methods Clin Dev. 2020 Nov 26;20:258-275
pubmed: 33473359
Gut. 2015 Dec;64(12):1961-71
pubmed: 25429051
Viruses. 2014 Feb 17;6(2):832-55
pubmed: 24549268
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088

Auteurs

Tasneem Farhad (T)

Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

Keila Neves (K)

Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

Patrick Arbuthnot (P)

Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

Mohube Betty Maepa (MB)

Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH